Intravitreal acetazolamide implant for pseudophakic cystoid macular edema

Rodrigo Jorge, Isabela Franco Villela, Christian Fernandes, Thais Marino de Azevedo Bastos, Ingrid U. Scott, Armando da Silva Cunha, Silvia Ligório Fialho, Pedro Henrique Reis da Silva, André Messias

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Pseudophakic cystoid macular edema (PCME) is the most common cause of visual acuity deterioration after uncomplicated cataract surgery. There is no consensus regarding how to manage recurrent or refractory cases. Report: A 54-year-old woman complained of decreased vision and central metamorphopsia in the right eye (OD) 3 months after uneventful cataract surgery. Visual acuity was 0.3 logMAR (20/40) OD and 0.1 logMAR (20/25) OS. Reduced macular brightness was seen OD on funduscopy associated with increased macular thickness on optical coherence tomography (OCT). Pseudophakic cystoid macular edema (PCME) was diagnosed, and treatment with oral acetazolamide was tried without success. The patient underwent a single intravitreal injection of an acetazolamide implant (260 μg) OD as off-label treatment. Four weeks following the injection, she reported complete resolution of her metamorphopsia and visual loss OD. Four months later, her visual acuity was 0.0 logMAR (20/20) in OD and 0.1 logMAR (20/25) in OS. The patient reported no discomfort after the injection procedure. Laboratory and ophthalmologic tests did not identify any adverse effects of the medication. Conclusion: We show that PCME refractory to conventional treatment improved after intravitreal acetazolamide implant injection. Further investigation is warranted to confirm these preliminary findings.

Original languageEnglish (US)
Pages (from-to)71-75
Number of pages5
JournalDocumenta Ophthalmologica
Issue number1
StatePublished - Aug 2023

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Physiology (medical)

Cite this